Evaluating the Role of Vitamin D3 in Modulating Insulin Resistance and Glycemic Control Among Type 2 Diabetic Nephropathy Patients
,
Abstract
Type 2 diabetes mellitus (T2DM) is a major global health concern, often complicated by diabetic nephropathy (DN), a leading cause of end-stage renal disease. Vitamin D3 has been implicated in various metabolic and inflammatory processes, potentially influencing insulin sensitivity and renal outcomes. However, the exact relationship between vitamin D3 levels, glycemic control, and insulin resistance in T2DM patients with different stages of DN remains unclear. This study aims to evaluate serum vitamin D3 levels in T2DM patients with varying degrees of albuminuria and to assess their correlation with markers of insulin resistance and glycemic control, compared with healthy controls. A case-control study was conducted involving 180 T2DM patients—divided into normoalbuminuria (n=60), microalbuminuria (n=60), and macroalbuminuria (n=60) groups—and 60 healthy controls. Glycemic Profile (Fasting blood glucose [FBS], HbA1c, fasting insulin), lipid profile (total cholesterol, triglycerides, LDL, HDL, VLDL), renal function markers (urea, creatinine, albumin-to-creatinine ratio [ACR], glomerular filtration rate [GFR]), calcium, and vitamin D3 levels were measured. Insulin resistance was assessed using the HOMA-IR index. Serum vitamin D3 levels were significantly lower in all T2DM subgroups than in controls (P<0.001), with the lowest levels observed in the macroalbuminuria group. A significant positive correlation was observed between vitamin D3 and FBS only in the microalbuminuria group (r= +0.437, P=0.016). No significant associations were found between vitamin D3 and HOMA-IR or other glycemic parameters across the groups. Markers of renal dysfunction, including serum creatinine, urea, and ACR, were significantly elevated with increasing severity of albuminuria. Vitamin D deficiency is prevalent in T2DM patients with nephropathy, especially those with advanced renal impairment. While no strong associations were found between vitamin D3 and insulin resistance, a positive correlation with FBS in early-stage nephropathy suggests a potential role for vitamin D in glycemic regulation during the progression of DN. Further longitudinal studies are warranted to explore the therapeutic implications of vitamin D supplementation in T2DM patients at risk of nephropathy.
2. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 2020;21:6275.
3. Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 2020;22:3-15.
4. Avogaro A, Fadini GP. Microvascular complications in diabetes: a growing concern for cardiologists. Int J Cardiol 2019;291:29-35.
5. Bhatti JS, Sehrawat A, Mishra J, Sidhu IS, Navik U, Khullar N, et al. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: current therapeutic strategies and future perspectives. Free Radic Biol Med 2022;184:114-34.
6. Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J 2022;46:15-37.
7. Contreras-Bolívar V, García-Fontana B, García-Fontana C, Muñoz-Torres M. Mechanisms involved in the relationship between vitamin D and insulin resistance: impact on clinical practice. Nutrients 2021;13:3491.
8. Yang Y, Zhang X, Bao M, Liu L, Xian Y, Wu J, et al. Effect of serum 25-hydroxyvitamin D3 on insulin resistance and β-cell function in newly diagnosed type 2 diabetes patients. J Diabetes Investig 2016;7:226-32
9. Del Gobbo LC, Song Y, Dannenbaum DA, Dewailly E, Egeland GM. Serum 25-hydroxyvitamin D is not associated with insulin resistance or beta cell function in Canadian Cree. J Nutr 2011;141:290-5.
10. Mitri J, Muraru M, Pittas A. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr 2011;65:1005-15.
11. Bikle D. Vitamin D: production, metabolism, and mechanisms of action. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
12. Fenercioglu AK. The anti-inflammatory roles of vitamin D for improving human health. Curr Issues Mol Biol 2024;46:13514-25.
13. Dashti N, Einollahi N, Nabatchian F. Leptin and interleukin-6 in end-stage renal disease. Pak J Med Sci 2008;24:694-7.
14. Majidi Z, Hosseinkhani S, Amiri-Dashatan N, Emamgholipour S, Tutunchi S, Hashemi J, et al. Effect of rosiglitazone on circulating malondialdehyde (MDA) level in diabetes based on a systematic review and meta-analysis of eight clinical trials. J Investig Med 2021;69:697-703.
15. Soltani A, Aghakhani A, Dehghanbanadaki H, Majidi Z, Rezaei-Tavirani M, Shafiee G, et al. Association between liver fibrosis and osteoporosis in adults aged 50 and older: insights from the Bushehr Elderly Health Program. J Diabetes Metab Disord 2025;24:65.
16. Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr 2004;79:820-5.
17. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, et al. Low serum 25-hydroxyvitamin D is associated with increased risk of metabolic syndrome at five years. J Clin Endocrinol Metab 2012;97:1953-61.
18. Safaie N, Idari G, Ghasemi D, Hajiabbasi M, Alivirdiloo V, Masoumi S, et al. AMPK activation: a potential strategy to mitigate TKI-induced cardiovascular toxicity. Arch Physiol Biochem 2024;1-13.
19. Wang Q, Sun J, Liu M, Zhou Y, Zhang L, Li Y. The new role of AMP-activated protein kinase in regulating fat metabolism and energy expenditure in adipose tissue. Biomolecules 2021;11:1757.
20. Chang E, Kim Y. Vitamin D ameliorates fat accumulation with AMPK/SIRT1 activity in C2C12 skeletal muscle cells. Nutrients 2019;11:2806.
21. Llorens-Cebrià C, Molina-Van den Bosch M, Vergara A, Jacobs-Cachá C, Soler MJ. Antioxidant roles of SGLT2 inhibitors in the kidney. Biomolecules 2022;12:143.
22. Li X, Liu Y, Zheng Y, Wang P, Zhang Y. The effect of vitamin D supplementation on glycemic control in type 2 diabetes patients: a systematic review and meta-analysis. Nutrients 2018;10:375.
23. Rohold CK, Jørgensen HL, Vojdeman FJ, Madsen CM, Olsen A, Heegaard AM, et al. Levels of plasma 25-hydroxy vitamin D and risk of developing type 2 diabetes in a large Danish primary health care population. Acta Diabetol 2025;62:397-404.
24. Zhou T, Shen L, Li Z, Jia J, Xing H, Wang N, et al. Severe 25-hydroxyvitamin D deficiency may predict poor renal outcomes in biopsy-proven diabetic nephropathy. Front Endocrinol 2022;13:871571.
25. Forouhi NG, Luan JA, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxyvitamin D predicts future glycemic status and insulin resistance: the Ely Prospective Study 1990–2000. Diabetes 2008;57:2619-25.
26. Cao M, He C, Gong M, Wu S, He J. The effects of vitamin D on all-cause mortality in different diseases: an evidence-map and umbrella review of 116 randomized controlled trials. Front Nutr 2023;10:1132528.
| Files | ||
| Issue | Vol 63 No 5 (2025) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/acta.v63i5.20350 | |
| Keywords | ||
| Diabetic nephropathy Microalbuminuria Vitamin D3 Insulin resistance Glycemic control Type 2 diabetes mellitus (T2DM) | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
